Table 1.
Characteristics of included studies for meta-analysis
| Author, year | Study design | Duration | Follow-up (months) | Number | Age (years) | Tumor stage (FIGO) | Histological type | Tumor grade | Treatment | Interval | Prognostic factor (cut-off values) and survival data (HRs and 95% CIs) | Adjusted covariates | NOS scores | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aoyama, 2019, Japan | Retrospective cohort study | 2007–2013 | 125 | 197 | Median, 59 | I–IV | Endometrioid, other | 1–3 | S | NR |
NLR (2.18) OS: 2.23 (0.68–9.96) in Ua; |
PLR (206) OS: 2.28 (0.74–7.72) in Ma |
Age at diagnosis, BMI, FIGO stage, histological type, malignant ascites | 7 |
| Cömert, 2018, Turkey [13] | Retrospective cohort study | 2006–2016 | Median, 24 | 497 | Mean, 58 | I–IV | Endometrioid, clear cell, serous, mucinous, mixed, undifferentiated | 1–3 | C, S, R | 8 ± 6 days |
NLR (2.06) DFS: 1.10 (0.56–2.15) in Ua; OS: 1.70 (0.66–4.40) in Ua |
PLR (168) DFS: 1.17 (0.55–2.51) in Ua; OS: 2.91 (1.15–7.36) in Ma; |
Stage | 7 |
| Takahashi, 2015, Japan [19] | Retrospective cohort study | 2000–2010 | 60 | 508 | Mean, 58 | I–IV | Endometrioid, non-endometrioid | 1–3 | C, S, R | NR |
NLR (3) OS: 2.47 (1.45–4.24) in Ua |
NR | NR | 6 |
| Li, 2015, China [21] | Retrospective cohort study | 2007–2009 | Mean, 51.2 | 282 | Median, 53 | I–IV | Endometrioid, non-endometrioid | 1–3 | C, S | Within 2 weeks |
NLR(4.68) OS: 2.298 (0.679–7.781) in Ma |
PLR (250) OS: 0.993 (0.294–3.357) in Ma |
Serum concentrations of CRP, D–D, CA125 and CA153 | 7 |
| Haruma, 2015, Japan [17] | Retrospective cohort study | 2002–2012 | 130 | 320 | Median, 57.5 | I–IV | Endometrioid, serous, carcinosarcoma, clear cell, mixed, adenosquamous, undifferentiated | 1–3 | C, S | Within a month |
NLR (2.41) DFS: 1.693 (0.888–3.229) in Ma; OS: 3.318 (1.154–9.538) in Ma |
PLR (175.72) DFS: 1.599 (0.922–2.772) in Ua; OS: 0.546 (0.192–1.552) in Ma |
FIGO stage, tumor histology, myometrial invasion, cervical invasion, lymph node metastasis, ovarian metastasis, peritoneal cytology, serum CA125 | 8 |
| Eo, 2016, Korea [16] | Retrospective cohort study | 2005–2014 | Median, 51.3 | 255 | Median, 44 | I–IV | Endometrioid, serous, mixed, clear cell, mucinous, squamous, undifferentiated | 1–3 | S | Within 2 weeks |
NLR (2.4) DFS: 3.68 (1.55–8.76) in Ua; OS: 3.47 (1.20–10.05) in Ua |
PLR (190.78) DFS: 3.08 (1.30–7.32) in Ua; OS: 2.89 (1.00–8.38) in Ua |
NR | 6 |
| Ding, 2017, China [12] | Retrospective cohort study | 2007–2013 | Mean, 65.84 | 185 | Mean, 59.29 | I–IV | Type I, type II | 1–3 | C, S, R | Within 7 days |
NLR (1.81) DFS: 2.71 (1.26–5.82) in Ma; OS: 3.91 (1.58–9.81) in Ma |
PLR (186.4) DFS: 2.98 (1.66–5.34) in Ua; OS: 3.68 (1.76–7.69) in Ua |
Tumor histology, FIGO stage | 8 |
| Cummings, 2015, UK [15] | Retrospective cohort study | 2005–2007 | Median, 81.5 | 605 | Median, 65 | I–IV | Endometrioid, serous, carcinosarcoma clear cell, mixed | 1–3 | C, S, R | Within 2 weeks |
NLR (2.4) OS: 1.82 (1.27–2.62) in Ma |
PLR (240) OS: 1.89 (1.30–2.75) in Ma |
Age, FIGO stage, grade, histopathological subtype, LVSI | 8 |
| Matsuo, 2015, USA [18] | Retrospective cohort study | 2003–2013 | Median, 35 | 541 | Mean, 52.1 | I–IV | Endometrioid, serous, clear cell, others | 1–3 | S | NR |
NLR (3) DFS: 1.65 (1.02–2.65) in Ua; OS: 2.18 (1.21–3.93) in Ua |
NR | NR | 6 |